September 13th, 2024 - PharmaResearch (co-CEOs: Kang Ki Seock, Kim Thinkyou), a leader in aesthetic injectables and regenerative medicines renowned for its flagship skin booster product “Rejuran”, announced a significant milestone in its global market expansion efforts, securing KRW 200 billion investment from Europe-based global private equity firm CVC through the issuance of redeemable convertible preferred shares (RCPS). Extending beyond capital injection, this investment will enable the company to accelerate overseas market entry through strategic partnership with CVC.
CVC is a leading global private equity firm that manages over €180 billion of AUM, and has a strong investment track record in the healthcare industry across Europe and other key global markets. PharmaResearch aims to leverage CVC’s extensive global network and experience to achieve rapid and stable penetration into new international markets. As a strategic partner, CVC will provide valuable network and resources to support PharmaResearch’s market expansion and strengthen the company’s global competitiveness.
PharmaResearch plans to utilize the newly secured funds primarily for strategic overseas M&As and the establishment of local subsidiaries to implement region-specific go-to-market strategies and rapidly expand its presence in these markets. The company also intends to utilize the funds to upgrade its R&D capabilities and expand its product pipeline through acquisitions. Investments in innovative product development as well as existing product enhancements are expected to strengthen the company’s product portfolio, leading to increased global competitiveness by delivering greater value to its international customers.
Kim Thinkyou, CEO of PharmaResearch, stated, "With CVC’s investment and partnership, PharmaResearch is now in a stronger position to enhance its global market presence and continue focusing on developing innovative products and services. We are committed to delivering value to our customers and shareholders as we continue our journey towards becoming a global leader.”
Kyoo-Cheol Chris Rhee, CVC’s Head of Korea, remarked, “CVC is delighted to partner with a company like PharmaResearch.” and added, “With our global network and experience, CVC is fully committed to supporting PharmaResearch’s continued growth in the global market and to contributing to the growth of the K-beauty industry globally.”
About PharmaResearch
PharmaResearch is a pioneering biopharmaceutical company dedicated to enhancing the quality of life for humanity through regenerative medicine. With a diverse portfolio encompassing medicines, medical devices, cosmetics, and supplements, PharmaResearch focuses on leveraging its core ingredients, DOT® PDRN and DOT® PN. These active tissue regenerative substances are powered by DOT®, an exclusive DNA fragments optimization technology safeguarded by a suite of patents. Headquartered in Seongnam, South Korea, PharmaResearch also operates a U.S. subsidiary, PharmaResearch USA, located in Costa Mesa, California. Key products include Rejuran®, Rejuviel®, Conjuran®, Rejuran® Cosmetics, Lian® Eye Drops, Rejuvenex Cream®, and Rejuderma®.
For more information about PharmaResearch and its innovative initiatives, visit http://pharmaresearch.co.kr/en/ and connect with us on LinkedIn.
Media Contact
Company Name: PharmaResearch USA
Contact Person: Sangjin Choi
Email: Send Email
Country: United States
Website: http://pharmaresearch.co.kr/en
